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BACKGROUND

Anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
is a rare and life-threatening autoimmune disease with severe
complications, including damage to various major organs. The disease is
caused by small blood vessel inflammation in which white blood cells
attack endothelial cells in blood vessel linings, inducing swelling and
hemorrhage. In the past, AAV was a fatal disease, but with timely
immunosuppressant treatment, the survival of AAV patients has significantly
improved. Nevertheless, AAV is still associated with frequent relapses and
significant irreversible damage.
Studies looking at the cognitive health outcomes of AAV patients with
central nervous system involvement have noted cognitive impairment as a
significant contributor to reduced quality of life with unique challenges in
care and treatment. It is important to evaluate the cognitive outcomes of
AAV patients to aid in early detection at various stages of disease
progression. In this output, we summarized the demographics and disease
characteristics of AAV patients recruited from renal-rheumatology vasculitis
clinics at St. Joseph’s Health Care and a glomerulonephritis clinic at
London Health Sciences Centre.

DATA & DISCUSSION
We recruited 37 patients (16 male and 21 female) between 18 and 75 years
old who meet the American College of Rheumatology classification criteria
for AAV. Fourteen patients had the active disease and 23 patients were in
remission. The patients had a mean age of 53.07 ± 14.18 at the time of
assessment. Disease characteristics (Figure 1) and disease scores (Figure 2)
are summarized.
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Figure 1. Summary of
organ involvement in
the patient cohort.

Absence of damage (VDI = 0)
22.8%
Severe Damage (VDI ≥ 5)
42.1%

Figure 2. Vasculitis Damage
Index (VDI) scores illustrating
vasculitis-induced chronic
damage.

Low to Moderate Damage (VDI 1-4)
35.1%

The data collected from this primary output could be combined with global
assessments of cognitive function as well as the application of advanced
imaging tools to study the relationship between vascular abnormalities,
disease activity and cognition. Our findings could prompt the use of noninvasive imaging to identify early signals of AAV complications and prevent
irreversible cognitive damage at all stages of disease progression.
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